BioSpace News Archive

Heru, a Bascom Palmer Eye Institute medical technology company developing a next-generation AI platform for vision diagnostics and augmentation, announces its class I listing with the U.S. Food and Drug Administration for its cloud-based augmented/virtual reality platform’s first diagnostic application for Visual Field Exams.

CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that the first participant in a clinical Phase 3 study with its COVID-19 vaccine, CVnCoV, in healthcare workers at the University Medical Center Mainz will be vaccinated on December 22, 2020.

The company and its CEO thank supporters and remain fully committed; company will also provide a series of GenViro! test results it has amassed demonstrating the technologys promise

OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today disclosed that the U.S. Food and Drug Administration (FDA) has requested additional information as part of its review of the Company’s application for Emergency Use Authorization (EUA) for its laboratory-based oral fluid SARS-CoV-2 antibody test. The OraSure SARS-CoV-2 Antibody ELISA is intended for qualitative detection

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), which became effective prior to market open on Monday, Decembe

Danaher Corporation (NYSE: DHR) announced today that Jose-Carlos (“JC”) Gutierrez-Ramos has been named Senior Vice President and Chief Scientific Officer for Danaher. In this role, Dr. Gutierrez-Ramos will have responsibility for helping define Danaher’s science and technology strategy across the organization, including facilitating i

Phase 1 Study Dose Escalation Ongoing in All HER2 Positive Tumor Types HER2 Positive Breast Cancer Expansion Cohort Planned to be Initiated in 1H21 Expansion Cohorts in Additional Tumors Types to Begin When MTD or Recommended Phase 2 Dose is Reached

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced it has been granted a licence by UniQuest, the commercialisation company of The University of Queensland (UQ), to novel zinc ionophore technology to combat antimic

CureDuchenne, a leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, announced today a new initiative to deliver free medical ID bracelets to individuals in the United States living with Duchenne. With an initial limited quantity of 1,200 bracelets supplied by MyID, a leading provider of medical bracelets, they will be distributed on a first-come-first-serve basis. Ea